Market Research Industry Reports

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. Tavalisse (fostamatinib disodium hexahydrate), the companys first US FDA approved product is an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company also has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc Key Recent Developments

May 01,2018: Rigel Reports First Quarter 2018 Financial Results
Mar 06,2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Dec 15,2017: Rigel Announces Departure of Chief Financial Officer
Nov 07,2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
Nov 02,2017: Rigel Welcomes Gregg Lapointe to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Rigel Pharmaceuticals Inc - Key Facts 5
Rigel Pharmaceuticals Inc - Key Employees 6
Rigel Pharmaceuticals Inc - Key Employee Biographies 7
Rigel Pharmaceuticals Inc - Major Products and Services 8
Rigel Pharmaceuticals Inc - History 9
Rigel Pharmaceuticals Inc - Company Statement 12
Rigel Pharmaceuticals Inc - Locations And Subsidiaries 13
Head Office 13
Section 2 Company Analysis 14
Rigel Pharmaceuticals Inc - Business Description 14
Rigel Pharmaceuticals Inc - Corporate Strategy 15
Rigel Pharmaceuticals Inc - SWOT Analysis 16
SWOT Analysis - Overview 16
Rigel Pharmaceuticals Inc - Strengths 16
Rigel Pharmaceuticals Inc - Weaknesses 17
Rigel Pharmaceuticals Inc - Opportunities 18
Rigel Pharmaceuticals Inc - Threats 19
Rigel Pharmaceuticals Inc - Key Competitors 20
Section 3 Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 Companys Lifesciences Financial Deals and Alliances 27
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Rigel Pharmaceuticals Inc, Recent Deals Summary 29
Section 5 Companys Recent Developments 30
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update 30
Dec 15, 2017: Rigel Announces Departure of Chief Financial Officer 32
Nov 07, 2017: Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update 33
Nov 02, 2017: Rigel Welcomes Gregg Lapointe to Board of Directors 34
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 35
Aug 25, 2017: Rigel Welcomes Brian Kotzin, M.D. to Board of Directors 36
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 37
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 38
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 39
Section 6 Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables

List of Tables
Rigel Pharmaceuticals Inc, Key Facts 5
Rigel Pharmaceuticals Inc, Key Employees 6
Rigel Pharmaceuticals Inc, Key Employee Biographies 7
Rigel Pharmaceuticals Inc, Major Products and Services 8
Rigel Pharmaceuticals Inc, History 9
Rigel Pharmaceuticals Inc, Key Competitors 20
Rigel Pharmaceuticals Inc, Ratios based on current share price 21
Rigel Pharmaceuticals Inc, Annual Ratios 22
Rigel Pharmaceuticals Inc, Annual Ratios (Cont...1) 23
Rigel Pharmaceuticals Inc, Interim Ratios 25
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Rigel Pharmaceuticals Inc, Recent Deals Summary 29
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44

List Of Figures

List of Figures
Rigel Pharmaceuticals Inc, Performance Chart (2013 - 2017) 24
Rigel Pharmaceuticals Inc, Ratio Charts 26
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125View Report

Rigel Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Rigel Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Rigel Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Threshold Pharmaceuticals Inc (MTEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Threshold Pharmaceuticals Inc (Threshold) is a biotechnology company that discovers and develops tumour-targeted therapies. The companys clinical pipeline includes TH-CR-406, MAESTRO, TH-CR-413, TH-CR-408, TH-IST-4003, TH-IST-4004, TH-CR-410, TH-CR-407 and TH-IST-4001. Its

USD 250View Report

Shuttle Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Shuttle Pharmaceuticals Inc (Shuttle), formerly Shuttle Pharmaceuticals LLC is a developer of therapies that offers novel drugs for improving cancer treatment outcomes. The companys pipeline products comprise therapies such as

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 125
  • Site Licence    USD 250
  • Enterprise Wide Licence    USD 375
$ 125

Reports Details

Published Date : Jun 2018
No. of Pages :45
Country :United States of America
Category :Swot Analysis
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube